Clinical trials: Stroke Prevention in Patients With Atrial Fibrillation
Atrial Fibrillation
Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.
- Trial name
- NCT03187197
- Testing
- Pradaxa®
- Where
- 24 sites in Taiwan
- Volunteers
- 1,315 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Stroke
LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke
This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with…
- Conditions
- Atrial Fibrillation, Stroke, Systemic Embolism
- Trial name
- 5A (NCT02478294)
- Testing
- Thoracoscopic LAA Excision plus AF Ablation, Warfarin or Novel Oral Anticoagulants
- Where
- China
- Volunteers
- 474 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Anticoagulation
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
- Trial name
- NCT02640222
- Testing
- VKA, Apixaban, dabigatran
- Where
- France
- Volunteers
- 321,501 people
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation (NVAF)
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions.
- Trial name
- XARENAL (NCT03746301)
- Testing
- Rivaroxaban(Xarelto,BAY 59-7939)
- Where
- South Korea
- Volunteers
- 924 people
- Sponsor
- Bayer
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for…
- Trial name
- AF-ALERT3 (NCT06355986)
- Testing
- Alert-based computerized decision support
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation (Prevention of Stroke)
Real-Life Evidence on Stroke Prevention in SPAF
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
- Trial name
- RELIEF (NCT02485873)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists
- Where
- Germany
- Volunteers
- 8,607 people
- Sponsor
- Bayer
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
- Trial name
- XANTUS (NCT01606995)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 6,784 people
- Sponsor
- Bayer
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists
The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.
- Trial name
- NCT02960880
- Testing
- Rivaroxaban (Xarelto, BAY597939), Phenprocoumon (branded and generics)
- Where
- Germany
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Atrial Fibrillation, Oral Anticoagulation
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO).
- Conditions
- Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
- Trial name
- INTERCEPT (NCT05723926)
- Testing
- Vine Filter
- Where
- 21 sites in United States, Brazil and 2 more
- Volunteers
- 2,000 people
- Sponsor
- Javelin Medical
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Stroke Prevention in Patients With Atrial Fibrillation
Long Term Open Follow-up With H376/95 vs. Warfarin
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
- Trial name
- NCT00206063
- Testing
- EXANTA
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Patient Convenience Study
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02597920
- Where
- 148 sites in Belgium, Denmark and 5 more
- Volunteers
- 1,852 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
This is a prospective, multi-center, randomized, pilot study comparing the WATCHMAN left atrial appendage occlusion device with Rivaroxaban therapy in patients with non-valvular atrial fibrillation.
- Trial name
- NCT02549963
- Testing
- WATCHMAN Left Atrial Appendage Occlusion Device, Rivaroxaban
- Where
- 9 sites in China
- Volunteers
- 200 people
- Sponsor
- Shulin Wu
Atrial Fibrillation
Stroke Prevention and Rhythm Control Therapy STEEER-AF
A prospective trial with hospitals/health centres across 6 different European countries, being randomised to either a structured education programme as the intervention or no additional education as the control.
- Trial name
- STEEER-AF (NCT04396418)
- Testing
- Education
- Where
- 70 sites in France, Germany and 4 more
- Volunteers
- 1,732 people
- Sponsor
- European Society of Cardiology
Atrial Fibrillation
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better…
- Trial name
- Naco_Nîmes (NCT02273700)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes